In this trial, risankizumab was found to result in ≥90% improvement in Psoriasis Area and Severity Index and static Physician’s Global Assessment at 16 weeks in patients with moderate psoriasis when compared to apremilast, with no new safety signals. http
12,384 followers
1,840 followers
21,735 followers
IMMpulse study - 1 yr OL, phase 4 trial of risankizumab (150 mg, wk 0, 4) vs apremilast (30 mg bid) in 352 pts w/ moderate plaque psoriasis. RIZ had superior efficacy at wk 16 w/ PASI90 score of 55.9% vs 5.1% for APR. https://t.co/dSLJA9Tsmx https://t.co/
1,841 followers
Le #risankizumab #Skyrizi* supérieur à l'#aprémilast #Otezla* dans le #psoriasis en plaques modéré https://t.co/aHSfS4lRia https://t.co/i9ud2KTxBK